FDA Adds Homeopathic Enforcement Details, Subtracts Compliance Policy Guide
Executive Summary
Revised draft guidance identifies types of homeopathics posing "higher risks to public health." FDA withdraws 1988 compliance policy guide that allows homeopathic to be available even though they are not subject to pre-market approval or other review process agency imposes on all other drugs.
You may also be interested in...
Avadim Adamant Its Support For Homeopathic Topical Ad Claims Meets FTC Standards
Avadim Health could get FTC scrutiny after it declines to comply with two findings by an industry self-regulation group to discontinue 26 claims for its Theraworx Relief homeopathic products. It says the analysis “misapplied the well-recognized standards of substantiation” established by FTC.
US COVID-19 Fraud: Oleander Stops Viral Duplication, Oral Rinse Delivers 30-Second Cure
Online claims and social media posts lead to warnings to Phoenix Biotechnology and Avila Herbals for claiming oleander homeopathic at 4X concentration can interfere with COVID-19 and other viruses’ duplication, and Rowpar Pharmaceuticals about a rapid cure provided by oral rinses and spray.
Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.